Mylan NV won a court ruling that invalidated a Sanofi patent on the Lantus SoloStar insulin pen, its blockbuster diabetes treatment.
The ruling, by U.S. District Judge Stanley Chesler in Newark, New Jersey, eliminated one obstacle for Mylan’s bid to sell a generic version. The invalidated patent, which expires in 2024, is one of several that Sanofi is using to prevent Mylan from selling a generic version of the insulin pen. In November, an appeals court said two other patents on the drug were invalid.
Sanofi American depositary receipts, which had been up 2.3%, erased gains on the ...
